What would #RSV vaccine mean for #Ghana's efforts to reduce #newborn & #child deaths? Dr Kwaku Poku Asante speaks... @KMAkandoh @mohgovgh @paedsociety_gh @GhanaPresidency @_GHSofficial @KhrcGhana @ReSViNET @RSVGOLD @gavi #STOPRSV #VaccinesWork @PMNCH @AccraReset

What would change for newborns if every pregnant woman got the #RSV vaccine? Dr @senjutisaha speaks... @chrfbd @MISDGHS @ReSViNET @RSVGOLD @gavi @UNICEFBD @WHO_BD #STOPRSV #WHA79 #VaccinesWork

What would change for newborns if every pregnant woman got the #RSV vaccine? Dr Ziyaad Dangor speaks... @WitsUniversity @WitsVIDA @CHAMPS_Health @paed_sa #STOPRSV #WHA79 #VaccinesWork @PMNCH @gavi @ReSViNET @RSVGOLD

Europe now has the tools to prevent severe RSV in infants—but many countries are not using them. ✍️ INSIDE VIEW: Andrew Ullmann & Michael Moore @WFPHA_FMASP @ECDC_EU @ReSViNET healthpolicy-watch.news/euro…

3 WEEKS TO REGISTER! Topic: The genetic basis of virus infection-induced asthma 📅 Date: Tuesday, April 28, 2026 ⌛ Time: 16:00–17:00 CEST ✍ Register: lnkd.in/eQJUe3ZY #Webinar #RSV #ReSViNET #CLARITY #Asthma #PrecisionMedicine #PublicHealth

Thank you for joining RSVVW’26. We are grateful to our global RSV community for making this conference in Rome such an inspiring and impactful event. From outstanding scientific sessions to meaningful discussions and connections. #RSVVW26 #RSV #ReSViNET

ReSViNET 2026 marked a clear shift from RSV vaccine science to real-world implementation. Strong discussions with Gates, WHO, Gavi, PATH & country leaders on governance, safety, ANC delivery & effectiveness. Focused strategy on Pakistan’s rollout The implementation era has begun.

My new startup, designed in ⁦@ReSViNET⁩ Paediatricians’ blood used to make new treatments for RSV and colds | New Scientist newscientist.com/article/251…

The @ReSViNET pesto. What else?

Catch up with Chief Scientific Officer Dr Andrew Catchpole our on-demand webinar on the world’s first RSV-B Human Challenge Model, developed at hVIVO. The webinar shares our world-leading expertise and insight into RSV virus isolation, GMP manufacturing, and the robust clinical data supporting vaccine and antiviral development. By watching the recording, you’ll gain a comprehensive understanding of our end-to-end human challenge trial services, proven patient recruitment approach, and specialist laboratory capabilities, alongside insights into RSV-hMPV-PIV trivalent challenge platform readiness and key comparative data on RSV-B versus RSV-A infection dynamics and incidence rates. 📍 Heading to RESVINET? Schedule a meeting with our team or look out for hVIVO onsite to discuss how our RSV-B and broader challenge models can support your development programmes. 🎥 Watch the full webinar recording: hvivo.com/rsv-b-webinar/?utm… 📩 bd@hvivo.com #RSV #RSVB #HumanChallengeModel #CHIM #VaccineDevelopment #AntiviralResearch #RespiratoryVirus #ClinicalTrials #RESVINET

Reminder 🔔 If you are heading to @ReSViNET's RSVVW'26 Conference then schedule a meeting today! As the world leader in human viral challenge studies and respiratory disease models, hVIVO is proud to contribute to the conversation on advancing RSV preventative and therapeutic innovation. With our RSV-A and RSV-B models—including the only commercially available RSV-B model—supported by integrated virology and immunology services, we are uniquely positioned to accelerate the development of vaccines and antivirals. If you’re developing RSV or hMPV therapeutics, hVIVO offers the fastest, most controlled path to meaningful efficacy data. Learn more at Resvinet and meet with our experts: Alex Mann – Senior Director, Clinical Science Maria Menikou – Business Development Director Chris Forsdyke – Head of Laboratory Services Our colleagues will also be available for a discussion at hVIVO's dedicated booth (booth #3) Learn more: hvivo.com/rsvvw26conference/ #HVO #RSVVW #RSV #hMPV #Conference #Rome #Respiratory #ClinicalTrials

As drug developers know, RSV and hMPV programmes face real challenges — seasonal variability, slow recruitment, and long, unpredictable field trials can delay even the most promising candidates. At hVIVO, we’re addressing these barriers head‑on. As the world leader in human viral challenge studies and respiratory disease models, we provide the fastest, most controlled path to meaningful early‑phase efficacy data. As the world leader in human viral challenge studies and respiratory disease models, hVIVO is proud to contribute to the conversation on advancing RSV preventative and therapeutic innovation. With our RSV-A and RSV-B models—including the only commercially available RSV-B model—supported by integrated virology and immunology services, we are uniquely positioned to accelerate the development of vaccines and antivirals. If you’re developing RSV or hMPV therapeutics, hVIVO offers the fastest, most controlled path to meaningful efficacy data. Get the chance to connect with our hVIVO experts at booth 3 at the upcoming @ReSViNET conference in Rome on 17-20 Feburary: Alex Mann – Senior Director, Clinical Science Maria Menikou – Business Development Director Chris Forsdyke – Head of Laboratory Services Learn more: hvivo.com/rsvvw26conference/ #HVO #RSVVW #RSV #hMPV #Conference #Rome #Respiratory #ClinicalTrials #RSVa

Pleased to share that my pathology research, “Histopathological and Immunohistochemical Analysis of Fatal Pediatric RSV Pneumonia,” 🔬has been accepted at RSVVW’26, a global meeting on innovative RSV preventive and therapeutic strategies in Rome, Italy 🇮🇹 #Patholgy #ReSViNET

Last Call: Regular Fee Registration, Submit Your Abstract & Join the YRT at RSVVW’26. 📅 17–20 February 2026 📍 Rome, Italy 🔗 resvinet.org/conferences/rsv… #RSVVW26 #ReSViNET #RSVResearch #GlobalHealth #HealthConference #Rome2026

The RSV Chatbot is here to help you! Today, on World Pneumonia Day, RSV is highlighted specifically because it’s one of the leading causes of pneumonia in young children and adults over 65. #RSV #ReSViNET #PatientNetwork #Chatbot #QandA #Information #WorldPneumoniaDay

Prevention starts with small, simple steps: wash your hands, stay home when you’re sick, and ask your doctor about protection. Trust your instinct and protect your loved ones. 💚 #RSVPrevention #RSVAwarenessWeek2025 #ReSViNET #ProtectBabies #HealthyCommunities #BeRSVAware

We’ve invited none other than Louis Bont, paediatric infectious disease specialist. He leads a research group on RSV and in this video answers three key questions about the new RSV shot, Nirsevimab. #RSV #RSVAwarenessWeek2025 #ReSViNET

For the second day of RSV Awareness Week, we highlight the lasting impact of RSV on siblings. Oliver shares his story of losing his brother Alexander 16 years ago to RSV, a loss that still deeply affects him today. #RSVAwarenessWeek2025 #RSV #PatientVoice #FamilyStories #ReSViNET

We applaud @gavi’s newly announced support for establishing maternal vaccine programs against #RSV. Check out the RSV Roadshow to learn why RSV prevention is critical for infant health & survival and find tools to address it: path.org/who-we-are/programs… #VaccinesWork @ReSViNET @WHO

Professor Heather Zar from @FIRS_LungsFirst sees the new #lunghealth resolution from #WHA78 as an opportunity to ⬆️ access the new #RSV prevention tools. Read @Nakkazi in @LancetRespirMed👉 thelancet.com/journals/lanre… @ReSViNET @RSVGOLD @iRSVsociety @sbdrysdale @gateshealth